Nonetheless, patients harboring BRCA1/2 biallelic inactivation, biallelic inactivation in the HR pathway, or more than one somatic mutation in DDR-related genes exhibited longer overall survival (OS) time in comparison with their counterparts (Figures 2C–E), indicating their associations with better prognosis in ovarian cancer patients who received Pt-based chemotherapy. This evidence concerns the gene BRCA1 and ovarian cancer.